Peptide

Tirzepatide

Tirzepatide (dual GIP/GLP-1 receptor agonist)

Dual GIP and GLP-1 agonist with 22.5% weight loss in SURMOUNT-1. Fat mass reduction 3x greater than lean mass loss. No completed cardiovascular outcomes trial yet.

Editor approved

Summary Can tirzepatide help with weight loss and healthy aging? Show / hide ↓

Tirzepatide is a prescription medicine for type 2 diabetes and long-term weight management. It copies two body hormones that help control blood sugar, hunger, and digestion. In a 72-week study of 2,539 people, those taking the highest dose lost an average of 22.5% of their body weight, compared with 2.4% with placebo, an inactive treatment. A smaller body-scan study found that about 33.9% of fat mass was lost compared with 10.9% of lean mass, which includes muscle and other non-fat tissue. Nausea, diarrhea, vomiting, and constipation are common, and no completed study has yet shown that tirzepatide prevents heart attacks or extends life.

What this means for you: Tirzepatide has solid evidence for substantial weight loss, but its effects on lifespan and long-term heart health are not yet known. Muscle loss and digestive side effects remain important considerations.

moderate evidence

Research snapshot FDA and EMA approved for type 2 diabetes and obesity. SURMOUNT trials complete.

Updated 2026-10-01

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and obesity (Zepbound). It produces up to 22.5% weight loss in SURMOUNT trials. SURPASS-CVOT showed 20% reduction in major cardiovascular events in type 2 diabetes. It is the most potent approved weight-loss drug to date.

Evidence tierTier 1, Human RCT on the exact molecule

Typical doseOnce-weekly subcutaneous injection. Dose escalation starts at 2.5 mg/week, increasing at 4-week intervals to 5, 7.5, 10, 12.5, and 15 mg maintenance dose.

SafetyBoxed warning for thyroid C-cell tumors (rodent data). Contraindicated with MTC or MEN 2 history. Gastrointestinal effects (nausea, vomiting, diarrhea) common during titration. Pancreatitis risk documented. Lean mass loss of approximately 10.9% in SURMOUNT-1 despite favorable 3:1 fat-to-lean ratio.

CategoryDual GIP/GLP-1 receptor agonist (incretin peptide)

Last verified2026-08-08

Tirzepatide is the most potent approved weight-loss medicine in the incretin class. It is a prescription medicine approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

The mechanism extends beyond single GLP-1 agonism. Tirzepatide activates both GIP and GLP-1 receptors on a single synthetic peptide. Dual incretin agonism stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic pathways. The GIP component is proposed to add metabolic and adipose-tissue effects beyond GLP-1 agonism alone.

The SURMOUNT-1 trial (N=2,539, 72 weeks) established weight-loss efficacy: 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) versus 2.4% with placebo. At least 5% body weight reduction was achieved by 89% (5 mg) and 96% (10 mg and 15 mg) versus 28% placebo. These are the largest mean weight-loss percentages for any approved medicine in the incretin class.

Body composition data is more detailed than for semaglutide. SURMOUNT-1 reported approximately three-times-greater percent reduction in fat mass than lean mass: 33.9% fat mass reduction versus 10.9% lean mass reduction. A DXA substudy (N=160, 124 on tirzepatide) and the SURPASS-3 MRI substudy measured fat and lean mass changes in adults with and without type 2 diabetes. The 3:1 fat-to-lean loss ratio suggests a body-composition profile that partially spares muscle relative to total weight lost, though muscle loss still occurs.

No dedicated cardiovascular outcomes trial equivalent to semaglutide's SELECT has been completed. SURPASS-2 (N=1,879, 40 weeks) compared tirzepatide to semaglutide 1 mg on glycemic and weight endpoints in type 2 diabetes: tirzepatide 5 mg reduced HbA1c by 2.01 percentage points. But this was not a cardiovascular outcomes trial.

Safety is consistent with the GLP-1 class. Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) are the most common side effects. Tirzepatide carries the class boxed warning regarding thyroid C-cell tumors seen in rodent studies and is contraindicated with personal or family history of MTC or MEN 2.

Dosing follows a stepwise escalation: starting at 2.5 mg weekly, increasing at 4-week intervals through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maintenance dose of 5, 10, or 15 mg once weekly.

For longevity, the GIP component may confer additional metabolic effects on adipose tissue and lipid handling beyond GLP-1 agonism alone. General GLP-1-class anti-inflammatory and NASH resolution benefits are mechanistically relevant. The larger relative fat-mass loss versus lean-mass loss ratio is a favorable signal for body composition compared to simpler GLP-1 agonists, though sarcopenia remains a concern in absolute terms given the large total weight lost.

Related in the encyclopedia

Further reading